Chemical Name: 2-Methyl-4-(phenylmethyl)-1,2,4-thiadiazolidine-3,5-dione
Biological ActivitySelective non-ATP competitive inhibitor of GSK 3β (IC50 = 2 μM); thiadiazolidinone deriviative. Does not inhibit Cdk-1/cyclin B, CK-II, PKA or PKC at >100 μM. Reduces severity of L-dopa-induced dyskinesia in a Parkinson's disease in vivo model.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.
Martinez et al.
Inhibition of Glycogen Synthase Kinase-3β (GSK-3�) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
Xie et al.
No product specific FAQs exist for this product, however you mayView all Small Molecule FAQs
Reviews for TDZD 8
There are currently no reviews for this product. Be the first to review TDZD 8 and earn rewards!
Have you used TDZD 8?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image